阅读说明：本技术 一种生物标记物在制备用于诊断自闭症以及判断自闭症康复的产品中的应用 (Application of biomarker in preparation of product for diagnosing and judging recovery from autism ) 是由 殷卫海 张铭超 陶钺 李雨嘉 于 2019-01-04 设计创作，主要内容包括：本发明提供了一种生物标记物在制备用于诊断自闭症以及判断自闭症康复的产品中的应用,所述分子标记物为使用400nm至700nm之间的激发光激发受试者手臂内侧皮肤的自发荧光强度,所述自发荧光的波长范围在420nm至800nm之间。人体手臂内侧皮肤绿色自发荧光的强度越高、左右分布越不对称,则该被测试人的自闭症越严重。本应用无创、高效、简单、准确度高且重复性好。(The invention provides application of a biomarker in preparing a product for diagnosing and judging recovery from autism, wherein the molecular marker is the autofluorescence intensity of the skin on the inner side of an arm of a subject excited by exciting light between 400nm and 700nm, and the wavelength of the autofluorescence is between 420nm and 800 nm. The higher the intensity of the green autofluorescence of the skin on the inner side of the arm of the human body is, the more asymmetric the left-right distribution is, the more serious the autism of the tested human body is. The application is noninvasive, efficient, simple, high in accuracy and good in repeatability.)

1. Use of a biomarker for the preparation of a product for diagnosing and rehabilitating autism, wherein the molecular marker is the autofluorescence intensity of the skin inside the arm of a subject excited by excitation light between 400nm and 700nm, and the autofluorescence has a wavelength range between 420nm and 800 nm.

2. Use according to claim 1, wherein the excitation light range is preferably 460nm to 640nm, more preferably 460nm to 580 nm.

3. Use according to claim 1, wherein the received light range is preferably between 480nm and 700nm, more preferably between 500nm and 620 nm.

4. The use of claim 1, wherein the subject is determined to have autism when the fluorescence intensity of the medial skin of the arm of the subject is higher than the average fluorescence intensity of the medial skin of the arm of a non-autistic test person that has been determined.

5. The use of claim 1, wherein the higher the fluorescence intensity of the skin inside the arm of the subject, the more severe the autism is.

6. The use of claim 1, wherein the subject is determined to have autism when there is an asymmetry in the fluorescence intensity of the skin inside the arm on the left and right sides of the subject.

7. The use of claim 1, wherein the subject has a greater degree of autism when the fluorescence intensity of the skin inside the arm on the left and right sides of the subject is more asymmetric.

8. Use of a biomarker for the preparation of a product for the detection of autism, comprising the steps of:

(1) exciting the skin on the inner side of the arm of the patient by exciting light between 400nm and 700 nm;

(2) receiving autofluorescence between 420nm and 800 nm;

(3) analyzing the intensity of the autofluorescence to determine whether the disease is autism;

(4) and analyzing whether the intensity of the autofluorescence is symmetrical or not to determine whether the autism exists or not.

9. Use of a biomarker for the preparation of a product for detecting the degree of recovery from autism, comprising the steps of:

(1) exciting the skin on the inner side of the arm of the patient by exciting light between 400nm and 700 nm;

(2) receiving autofluorescence between 420nm and 800 nm;

(3) analyzing the autofluorescence intensity, and comparing the autofluorescence intensity with the autofluorescence intensity of the skin on the inner side of the arm of the patient in the past; if there is a decrease in intensity now, it is an indication that the patient has recovered.

Technical Field

The invention relates to the application of the autofluorescence intensity and left-right spatial distribution of the skin on the inner side of an arm as a biomarker in preparing products for diagnosing and judging the recovery of autism. More specifically, the present invention relates to a method for detecting the onset and degree of autism by comparing the distribution of autofluorescence of the skin on the inner side of the arm with the distribution of the fluorescence intensity on the left and right sides, and also to a method for evaluating the recovery and degree of recovery from autism.

Background

Autism, also known as autism, is a developmental disorder resulting from a nervous system disorder, manifested by an early failure to perform normal speech expression and social activities, and often by performing stereotyped, repetitive, and restrictive actions and behaviors. The incidence rate of people worldwide is about 1 percent at present, the proportion of male patients is greater than that of female patients, but the symptoms of the female patients are more serious than that of the male patients, and at least 70 percent of autistic patients are usually accompanied by other diseases. The prevalence of autism continues to rise from the first epidemiological survey, and the data show that the prevalence of autism in the uk is 4.1/10000.

There is currently no method for early diagnosis of autism. Clinically, autism can only be diagnosed when it has clinical manifestations. Also, there is no good method for evaluating the efficacy. Therefore, the invention provides a novel, noninvasive, simple and convenient method for detecting the autism, which can be used at home, and has great social and economic significance and clinical value.

Disclosure of Invention

The invention aims to break through the difficult problems in the prior art and provides a novel detection method and application which can be used for detecting autism and has no damage to human bodies.

The specific technical scheme of the invention is as follows:

use of a biomarker for the preparation of a product for diagnosing and prognosing autism, wherein the molecular marker is the autofluorescence intensity of the skin on the inner side of the arm of a subject excited by excitation light between 400nm and 700nm, and the autofluorescence wavelength ranges between 420nm and 800 nm.

The inventor detects the green autofluorescence of the inner side skin of the arm of a subject, and finds that the green autofluorescence of the inner side skin of the arm of an autistic patient is obviously higher than that of a non-autistic patient after detection, and only the autistic patient shows a state that the green autofluorescence of the inner side skin of the arm is asymmetric left and right. And the higher the fluorescence intensity and the higher the left-right asymmetry, the higher the severity of autism. The invention relates to a method for detecting a new biomarker for judging autism by using the rising of green autofluorescence of skin on the inner side of an arm and the left and right asymmetry of the green autofluorescence of the skin on the inner side of the arm and application of the method.

Meanwhile, the inventor finds that the green autofluorescence intensity of the skin on the inner side of the arm of the recovery population for the autism is obviously lower than that of the skin on the inner side of the arm of the autism population, and the human autofluorescence bilateral symmetry degree is also higher than that of the autism population. And the lower the fluorescence intensity, the lower the left-right asymmetry, the higher the degree of autism recovery.

We found that the green autofluorescence intensity of the skin on the inner side of the arm was significantly increased in the autism population compared to the healthy population, but the autofluorescence did not significantly change in all the positions of the palm.

In one embodiment, the method further comprises determining that the subject has autism when the excitation light excites the skin on the inner side of the arm of the subject to have an autofluorescence intensity value higher than the autofluorescence intensity value of the skin on the inner side of the arm of the non-autistic patient.

In one embodiment, the subject is determined to have autism when the excitation light excites a significant difference in autofluorescence intensity of the skin on the inside of the arm of the left and right hands of the subject.

In one embodiment, the greater the difference in autofluorescence values at the bilateral symmetry of the subject's body surface excited by the excitation light, the more severe the autism is.

In a particular embodiment, the excitation light range is preferably 460nm to 640nm, more preferably 460nm to 580 nm.

In a particular embodiment, the received light range is preferably between 480nm and 700nm, more preferably between 500nm and 620 nm.

In another aspect, the present invention discloses a method for detecting autism, wherein the method comprises the following steps:

(1) exciting the skin on the inner side of the arm of the patient by exciting light between 400nm and 700 nm;

(2) receiving autofluorescence between 420nm and 800 nm;

(3) the intensity of the autofluorescence was analyzed to determine whether or not autism was present.

In one embodiment, the method further comprises determining that the subject has autism when the excitation light excites the skin on the inner side of the arm of the subject to have an autofluorescence intensity value higher than the autofluorescence intensity value of the skin on the inner side of the arm of the non-autistic patient.

In one embodiment, the subject is determined to have autism when the excitation light excites a significant difference in autofluorescence intensity of the skin on the inside of the arm of the left and right hands of the subject.

In one embodiment, the greater the difference in autofluorescence values at the bilateral symmetry of the subject's body surface excited by the excitation light, the more severe the autism is.

In another aspect, the invention discloses a method for detecting the recovery degree of autism, wherein the method comprises the following steps:

(1) exciting the skin on the inner side of the arm of the patient by exciting light between 400nm and 700 nm;

(2) receiving autofluorescence between 420nm and 800 nm;

(3) the intensity of autofluorescence was analyzed to determine if autism was restored.

In one embodiment, when the excitation light excites the autofluorescence intensity value of the skin on the inner side of the arm of the subject suffering from autism to be lower than the average autofluorescence intensity value of the skin on the inner side of the arm of the autistic patient, the recovery from autism of the subject is determined.

In one embodiment, when the excitation light excites the autofluorescence intensity value of the skin on the inner side of the arm of the subject suffering from autism to be lower than the autofluorescence intensity value of the skin on the inner side of the arm of the autistic patient, the recovery of autism of the subject is determined.

In one embodiment, when the excitation light excites the autofluorescence intensity value of the skin on the inner side of the arm of the subject suffering from autism lower than the autofluorescence intensity value of the skin on the inner side of the arm of the patient suffering from autism, the recovery from autism of the subject is determined.

In one embodiment, when the excitation light excites the autofluorescence intensity value of the skin on the inner side of the arm of the subject suffering from autism lower than the autofluorescence intensity value of the skin on the inner side of the arm of the patient suffering from autism, the recovery from autism of the subject is determined.

In one embodiment, when the excitation light excites the autofluorescence intensity value of the skin on the inner side of the arm of the autistic subject to be lower than the autofluorescence intensity value of the skin on the inner side of the arm of the autistic patient, the recovery from autism of the subject is determined.

In one embodiment, when the excitation light does not significantly differ in the autofluorescence intensity values of the skin inside the left and right arms of the autistic subject, the recovery from autism of the subject is determined.

The invention has performed a large number of experiments, and also performed the body surface fluorescence of many other disease patients, and the body surface fluorescence of healthy people.

Drawings

Figure 1 shows a representative graph of autofluorescence intensity for detecting various skin locations, either autism or non-autism, using blue light excitation.

Detailed Description

The present invention will be further illustrated by the following detailed description.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

As used herein, the terms "autofluorescence," "auto-fluorescence," are interchangeable and refer to the phenomenon in which a tissue, cell, or biological substance absorbs the energy of excitation light into an excited state after being irradiated with excitation light of an appropriate wavelength, and emits light longer than the wavelength of the excitation light when exiting the excited state, wherein autofluorescence is light longer than the wavelength of the excitation light.

As used herein, the term "excitation light" refers to light capable of exciting a biomolecule to undergo an autofluorescence phenomenon, which should be shorter in wavelength than the autofluorescence.

As used herein, superficial fluorescence refers to the entire surface of the skin tissue of the human body.

Autism, also known as autism or autistic disorder, is a representative disease of pervasive developmental disorders.